In clinical trials, it has demonstrated significant weight loss effects, leading to its FDA approval for the following indication and usage: WEGOVY is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adult patients with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition
Liposomal technology changes the paradigm of nutraceuticals from quantity to quality: Not how much you consume, but how much your body absorbs
Dehydration on semaglutide manifests as headaches, dizziness , constipation, fatigue, dry mouth, and dark urine
Important disclaimer: Retatrutide is an investigational drug not yet approved by the FDA
A., Beier, D
By advocating for accessible treatments, supporting individuals on their weight loss journeys, and pushing for systemic change, Ivim Health is dedicated to sustaining the momentum that has led to this historic shift in obesity rates
